An Efficacy and Safety Trial of MK-8931 in Mild to Moderate Alzheimer's Disease (P07738) (EPOCH)

Conditions

Alzheimer´s Disease

What is the purpose of this trial?

The purpose of this study is to assess the efficacy and safety of MK-8931 compared with placebo in the treatment of Alzheimer's Disease(AD). The primary study hypotheses are that at least one MK-8931 dose is superior to placebo at 78 weeks of treatment with respect to change from Baseline in Alzheimer's Disease Assessment Scale Cognitive Subscale(ADAS-Cog) score and that at least one MK-8931 dose is superior to placebo at 78 weeks of treatment with respect to change from Baseline in Alzheimer's Disease Cooperative Study Activities of Daily Living Inventory(ADCS-ADL) score.


Participation Guidelines

Age:
55 Years - 85 Years
Gender:
Both

Click here for detailed information about who can participate in this trial.


Sponsor:
Merck Sharp & Dohme
Dates:
06/19/2013
Last Updated:
Study HIC#:
1204009991